|1.||Wolfgang, Curt D: 2 articles (04/2008 - 04/2008)|
|2.||Weiden, Peter J: 2 articles (04/2008 - 04/2008)|
|3.||Cutler, Andrew J: 2 articles (04/2008 - 04/2008)|
|4.||Weizman, Abraham: 2 articles (05/2003 - 03/2003)|
|5.||Poyurovsky, Michael: 2 articles (05/2003 - 03/2003)|
|6.||Morimoto, Tomoki: 1 article (04/2015)|
|7.||Shimizu, Saki: 1 article (04/2015)|
|8.||Sobue, Akira: 1 article (04/2015)|
|9.||Fujiwara, Mai: 1 article (04/2015)|
|10.||Ohno, Yukihiro: 1 article (04/2015)|
|1.||Schizophrenia (Dementia Praecox)
01/01/2001 - "M-100907 is a highly selective 5-HT2A antagonist that is being developed by Aventis Pharmaceuticals, formerly Hoechst Marion Roussel (HMR), for the potential treatment of schizophrenia. "
04/01/1999 - "1. There has been considerable research in the field of schizophrenia over the past few years with emphasis on the discovery of better drugs, particularly those with 5-HT2 antagonist activity. "
03/01/2003 - "Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study."
06/01/1999 - "Iloperidone (HP-873) is a 5-HT2 antagonist from Hoechst Marion Roussel Inc in clinical trials for the treatment of schizophrenia and psychosis. "
03/01/1999 - "Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia."
04/01/2005 - "The protective effects of sarpogrelate (SG), a 5-HT2A antagonist, were investigated in perfused guinea-pig Langendorff hearts subjected to ischemia and reperfusion. "
11/01/1992 - "In the histopathological study the effect of 8 mg/kg ritanserin, a 5-HT2 antagonist, administered continuously from 30 minutes prior to ischemia until 1 hour of recirculation was evaluated in five rats subjected to 10 minutes of ischemia. "
02/04/1994 - "Effects of naftidrofuryl oxalate (naftidrofuryl), a 5-HT2 antagonist, on neuronal damage and local cerebral blood flow was examined in a gerbil model of transient forebrain ischemia. "
05/01/2002 - "Based on effective outcomes in previous studies using fluoxetine (a 5-HT reuptake inhibitor) and ritanserin (a 5-HT2A antagonist), it was hypothesized that nefazodone, which is both a serotonin (5-HT) reuptake inhibitor (rather weak) and a 5-HT2A receptor antagonist, may provide an effective treatment for patients with dysthymic disorder. "
|4.||Psychomotor Agitation (Akathisia)
03/01/1999 - "To evaluate the efficacy of the 5-HT2 antagonist, mianserin in neuroleptic-induced akathisia. "
05/01/2003 - "Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone."
03/01/1999 - "Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. "
01/01/1990 - "Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin."
06/01/1995 - "In the presented case fluvoxamine-induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin. "
|5.||Body Weight (Weight, Body)
03/22/2007 - "Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model."
01/01/1987 - "The effects of the 5-HT2 antagonist pirenperone on temperature preference were observed 1 hr after injection in mice aged 3, 5 and 7 days and at doses of 0.16, 0.48 and 1.6 mg/kg body weight. "
01/01/1993 - "A specific 5-HT2 antagonist (metrenperone, 0.05 mg/kg of body weight) was administered IM 30 minutes before the cattle were given a 5-minute IV 5-HT infusion. "
11/01/2009 - "Olanzapine (2 mg/kg) and the 5-HT2C antagonist SB 243213 (1 mg/kg), but not the histamine H1 antagonist mepyramine (1 mg/kg), produced significant increases in percentage body weight above vehicle; olanzapine showed a significantly greater effect than SB 243213. "
|2.||Serotonin (5 Hydroxytryptamine)
|4.||5-HT2A Serotonin Receptor (5 HT2A Receptor)
|1.||Induced Hyperthermia (Thermotherapy)